Literature DB >> 21463537

Postpartum haemorrhage: prevention.

David Chelmow1.   

Abstract

INTRODUCTION: Loss of more than 500 mL of blood following childbirth is usually caused by failure of the uterus to contract fully after delivery of the placenta, and occurs in over 10% of deliveries, with a 1% mortality rate worldwide. Other causes of postpartum haemorrhage include retained placental tissue, lacerations to the genital tract, and coagulation disorders. Uterine atony is more likely in women who have had a general anaesthetic or oxytocin, an over-distended uterus, a prolonged or precipitous labour, or who are of high parity. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of non-drug interventions and of drug interventions to prevent primary postpartum haemorrhage? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 40 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: active management of the third stage of labour, carboprost injection, controlled cord traction, ergot compounds (ergometrine/methylergotamine), immediate breastfeeding, misoprostol (oral, rectal, sublingual, or vaginal), oxytocin, oxytocin plus ergometrine combinations, prostaglandin E2 compounds, and uterine massage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463537      PMCID: PMC3275142     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  33 in total

1.  A randomised evaluation of two techniques of management of the third stage of labour in women at low risk of postpartum haemorrhage.

Authors:  P L Giacalone; J Vignal; J P Daures; P Boulot; B Hedon; F Laffargue
Journal:  BJOG       Date:  2000-03       Impact factor: 6.531

2.  Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section.

Authors:  N Vimala; S Mittal; S Kumar
Journal:  Int J Gynaecol Obstet       Date:  2005-12-15       Impact factor: 3.561

3.  Placebo-controlled randomized comparison of vaginal with rectal misoprostol in the prevention of postpartum hemorrhage.

Authors:  Okan Ozkaya; Mekin Sezik; Hakan Kaya; Raziye Desdicioglu; Ralf Dittrich
Journal:  J Obstet Gynaecol Res       Date:  2005-10       Impact factor: 1.730

4.  Ergometrine or oxytocin? Blood loss and side-effects at spontaneous vertex delivery.

Authors:  D D Moir; A B Amoa
Journal:  Br J Anaesth       Date:  1979-02       Impact factor: 9.166

5.  Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor.

Authors:  Gunjan Singh; Gita Radhakrishnan; Kiran Guleria
Journal:  Int J Gynaecol Obstet       Date:  2009-07-22       Impact factor: 3.561

6.  Side effects of oral misoprostol for the prevention of postpartum hemorrhage: results of a community-based randomised controlled trial in rural India.

Authors:  Shobhana S Patted; Shivaprasad S Goudar; Vijaya A Naik; Mrutyunjaya B Bellad; Stanley A Edlavitch; Bhalchandra S Kodkany; Ashlesha Patel; Hrishikesh Chakraborty; Richard J Derman; Stacie E Geller
Journal:  J Matern Fetal Neonatal Med       Date:  2009-01

7.  Oral misoprostol for the prevention of primary post-partum hemorrhage during third stage of labor.

Authors:  Christopher A Enakpene; Imran O Morhason-Bello; Evbu O Enakpene; Ayodele O Arowojolu; Akinyinka O Omigbodun
Journal:  J Obstet Gynaecol Res       Date:  2007-12       Impact factor: 1.730

8.  A study of prophylactic use of 15-methyl prostalglandin F2alpha in the active management of third stage of labour.

Authors:  Arati Biswas; Runa Bal; Mrinal Kanti Kundu; Amit Kyal; Modhusudan Halder
Journal:  J Indian Med Assoc       Date:  2007-09

9.  Rectal misoprostol versus intravenous oxytocin for prevention of postpartum hemorrhage.

Authors:  Ahmed Nasr; Ahmed Y Shahin; Ali M Elsamman; Mahmoud S Zakherah; Omar M Shaaban
Journal:  Int J Gynaecol Obstet       Date:  2009-02-26       Impact factor: 3.561

10.  A pilot randomized controlled trial of controlled cord traction to reduce postpartum blood loss.

Authors:  Fernando Althabe; Alicia Alemán; Giselle Tomasso; Luz Gibbons; Gerardo Vitureira; José M Belizán; Pierre Buekens
Journal:  Int J Gynaecol Obstet       Date:  2009-06-21       Impact factor: 3.561

View more
  4 in total

Review 1.  A contemporary review of peripartum cardiomyopathy.

Authors:  Peysh A Patel; Ashwin Roy; Rabeia Javid; John Aw Dalton
Journal:  Clin Med (Lond)       Date:  2017-07       Impact factor: 2.659

Review 2.  Misoprostol to reduce intraoperative and postoperative hemorrhage during cesarean delivery: a systematic review and metaanalysis.

Authors:  Agustín Conde-Agudelo; Aníbal Nieto; Anyeli Rosas-Bermudez; Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2013-03-15       Impact factor: 8.661

3.  Does prolonged labor affect the birth experience and subsequent wish for cesarean section among first-time mothers? A quantitative and qualitative analysis of a survey from Norway.

Authors:  L C Gaudernack; T M Michelsen; T Egeland; N Voldner; M Lukasse
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-08       Impact factor: 3.007

4.  Association of primary postpartum hemorrhage with inter-pregnancy interval in urban South Ethiopia: A matched nested case-control study.

Authors:  Belayneh Hamdela Jena; Gashaw Andargie Biks; Yigzaw Kebede Gete; Kassahun Alemu Gelaye
Journal:  PLoS One       Date:  2022-07-18       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.